Cyclosporine A (CsA) may be bound to and released from the inner surface of central venous catheters resulting in spuriously elevated blood drug levels. We observed this phenomenon in a boy transplanted because of aplastic anemia up to 9 weeks after CsA had been switched from intravenous to oral administration. In comparison to phlebotomy, simultaneous blood sampling from the double lumen catheter resulted in a greater than 10-fold, or two-fold increase in drug levels, respectively, depending on whether or not the line used for prior CsA infusion was selected. Thus, prolonged binding of CsA to the inner surface of venous catheters should also be considered during oral administration.
Cyclosporine A (CsA) is an established drug for prevention of graft-versus-host-disease (GVHD) following hematopoietic stem cell transplantation and it can be administered intravenously or orally. 1 It has been repeatedly shown that CsA binds to the inner surface of silastic, silicon or polyurethane central venous catheters. [2] [3] [4] [5] Blood collected from these catheters may result in falsely elevated drug levels. Therefore, where single-lumen catheters are present CsA drug levels should be taken from a peripheral vein, and in double-lumen catheters from the lumen not used for CsA infusion. [2] [3] [4] [6] [7] [8] [9] We report the presence of spuriously elevated CsA drug concentrations in specimens taken from a catheter during oral CsA administration.
A double-lumen silicon catheter with identical lumina (Quinton Raaf 2; Kendall, Bothell, WA, USA) was inserted into an 11-year-old boy with severe aplastic anemia prior to bone marrow transplantation from his HLA-identical brother. Conditioning consisted of cyclophosphamide 50 mg/kg once daily i.v. for 4 days (total dose 200 mg/kg) and anti-lymphocyte globulin 0.75 ml/kg once daily i.v. for 4 days (total dose 3.0 ml/kg). GVHD prophylaxis included CsA (3 mg/kg) and short-course methotrexate (15 mg/m 2 at day ϩ1 and 10 mg/m 2 at days ϩ3, ϩ6 and ϩ11, respectively). CsA was administered from day Ϫ1 to ϩ23 as a 12 h infusion always through the same catheter lumen (port B). EDTA whole blood samples were collected 8 h after the end of the infusion from port A. CsA trough levels, as determined by monoclonal immunoassay (EMIT; Dade Behring, Liederbach, Germany) twice weekly ranged between 56 and 140 ng/ml (therapeutic range: 100-200 ng/ml). Beginning on day ϩ24, CsA was given orally (5 mg/kg in two daily doses). When the boy was being followed as an out-patient, a blood level inadvertently drawn from port B 2 weeks later was Ͼ500 ng/ml (outside the upper range of the assay). A blood sample was then drawn correctly from port A the next day and a CsA level of 118 ng/ml was determined. We were surprised by the finding that 2 weeks after switching from intravenous to oral administration CsA was still being released from the line used for prior infusion. Therefore, during the next visits, samples were collected in parallel from both lines in order to monitor the persistence of this phenomenon. As shown in Figure 1 , CsA levels taken from port B were spuriously elevated until day ϩ92, that is for 9 weeks after the last intravenous administration. We then studied the kinetics of drug release into the catheter lumina. After withdrawal of 5 ml of blood, fractionated sampling (six fractions of 5 ml blood at 5 s intervals) was performed by simultaneous collection from both catheter ports and a peripheral vein at day ϩ58 ( Table 1) . The blood CsA level obtained from the peripheral vein was 55 ng/ml. However, the CsA blood level determined from the first sample of port A (not used for prior CsA infusion) was 203 ng/ml, while the levels of the subsequent fractions ranged from 111 to 138 ng/ml (median: 121 ng/ml). In contrast, all six levels from the fractions taken from port B were outside the upper range of the assay (Ͼ500 ng/ml). When the catheter was removed at day ϩ181 (24 weeks after the last intravenous CsA infusion and 11 weeks after the last determination of CsA drug levels) no abnormalities in the lumen either of line A or line B could be detected on gross macroscopic examination. However, microscopic examination of the inner lumen was not undertaken.
Our observations demonstrate that the following phenomena have to be considered when CsA drug levels are taken from central venous lines:
(1) Regular flushing of the catheter line with saline 0.9% and heparin (200 U) three times weekly, respectively, as well as withdrawal of several ml of blood from the catheter before taking diagnostic samples (5 ml in the case reported here) were not sufficient to allow correct drug levels to be taken. (2) Blood samples obtained from the catheter lumen which has been used for prior CsA infusion may give falsely elevated results. This phenomenon may persist for several weeks after changing CsA administration from the intravenous to the oral route -in the case described here this lasted for more than 60 days after intravenous administration was stopped. There is only one similar report in the literature on this phenomenon published by Lorenz et al, 10 who demonstrated highly elevated drug levels 4 and 9 days after discontinuation of intravenous CsA. In that report, CsA drug levels were lowered after prior withdrawal of 5 ml blood from both lumina as concentrations decreased from Ͼ2000 g/l to 848 g/l and 493 g/l to 289 g/l, respectively. This contrasts to our observations where even the sixth of six 5 ml fractions collected within 5 s intervals exhibited drug levels elevated outside the upper threshold of the assay (500 ng/ml) ( Table 1) . We speculate that this phenomenon may be caused during the sampling procedure by the release of small CsA plaques from the internal catheter wall used for prior CsA infusion. (3) The mechanism allowing spuriously elevated CsA drug levels in samples taken from a line not used for prior CsA infusion remains to be elucidated. Drug levels in the case reported here were two-to four-fold higher than those simultaneously obtained by peripheral venipuncture. Diffusion of adsorbed CsA from the silastic material into the catheter lumen may be responsible for this phenomenon as only the first of six rapidly collected consecutive fractions showed the highest value (Table 1 ).
We therefore conclude that CsA drug levels obtained from double-lumen central catheters should be interpreted cautiously when discrepancies are observed between the dose administered and measured drug concentrations. In this situation, an additional sample taken from a peripheral vein may be helpful in avoiding misdiagnosis.
